Abstract
The authors previously showed that interferon regulatory factor (IRF)4 knockout mice are protected from experimental oxazolone and TNBS colitis. Here the effect of IRF4 on the expression of pro- and anti-inflammatory cytokines in TNBS colitis and long-term CD45RBhigh transfer colitis is examined. In TNBS colitis, no differences were found in interleukin (IL)-18 and tumor necrosis factor (TNF)-α expression between IRF4 knockout and wild-type mice. However, significant differences were detected in IL-6 and IL-17 production. Upon treatment with hyper-IL-6, IRF4–/– mice lost their protective properties towards TNBS application. Hyper-IL-6 application induced IL-6 mRNA, but not IL-17 mRNA expression, suggesting that IL-6 deficiency is not primarily responsible for the lack of IL-17 production. T-bet and GATA-3 mRNA expressions were not affected upon IL-6 application. In transfer colitis, colonic cytokine mRNA analysis revealed a reduced production of IL-6 in IRF4–/– reconstituted mice in the long-term course. In contrast, several other cytokines did not differ between the two groups (e.g. TNF-α and IL-10). Measurement of supernatants from splenic mononuclear cells revealed a significant difference in IL-6 and IL-17 production between the two groups. These findings suggest that IRF4 selectively regulates cytokine gene expression in chronic inflammation. IRF4 therefore emerges as an attractive target for the therapy of chronic intestinal inflammation. Blocking IRF4 might be an interesting option to modulate inflammation in the advanced state of inflammation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Atreya R, Mudter J, Finotto S et al (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 6: 583–588
Autenrieth IB, Bucheler N, Bohn E et al (1997) Cytokine mRNA expression in intestinal tissue of interleukin-2 deficient mice with bowel inflammation. Gut 41: 793–800
Blumberg RS, Saubermann LJ, Strober W (1999) Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 11: 648–656
Boirivant M, Fuss IJ, Chu A et al (1998) Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 188: 1929–1939
Brustle A, Heink S, Huber M et al (2007) The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol 8: 958–966
Ivanov II, McKenzie BS, Zhou L et al (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126: 1121–1133
Lohoff M, Mak TW (2005) Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat Rev Immunol 5: 125–135
Lohoff M, Mittrucker HW, Prechtl S et al (2002) Dysregulated T helper cell differentiation in the absence of interferon regulatory factor 4. Proc Natl Acad Sci USA 99: 11808–11812
Macdonald TT, Monteleone G (2005) Immunity, inflammation, and allergy in the gut. Science 307: 1920–1925
Morrissey PJ, Charrier K, Braddy S et al (1993) CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J Exp Med 178:237–244
Mudter J, Amoussina L, Schenk M et al (2008) The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J Clin Invest 118: 2415–2426
Mudter J, Neurath MF (2003) Mucosal T-cells: mediators or guardians of inflammatory bowel disease. Curr Opin Gastroenterol 19: 343–349
Mudter J, Neurath MF (2007) IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 13: 1016–1023
Mudter J, Wirtz S, Galle PR et al (2002) A new model of chronic colitis in SCID mice induced by adoptive transfer of CD62L+ CD4+ T cells: Insights into the regulatory role of interleukin-6 on apoptosis. Pathobiology 70: 170–176
Neurath MF, Fuss I, Kelsall BL et al (1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182: 1281–1290
Neurath MF, Weigmann B, Finotto S et al (2002) The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn’s disease. J Exp Med 195: 1129–1143
Ogura H, Murakami M, Okuyama Y et al (2008) Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 29: 628–636
Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347: 417–429
Powrie F, Leach MW, Mauze S et al (1993) Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 5: 1461–1471
Rengarajan J, Mowen KA, McBride KD et al (2002) Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. J Exp Med 195: 1003–1012
Sartor RB (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126:1620–1633
Shanahan F (2002) Crohn’s disease. Lancet 359: 62–69
Strober W, Fuss IJ, Blumberg RS (2002) The immunology of mucosal models of inflammation. Annu Rev Immunol 20: 495–549
Wehkamp J, Schmid M, Fellermann K et al (2005) Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn’s disease. J Leukoc Biol 77: 460–465
Wirtz S, Becker C, Blumberg R et al (2002) Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J Immunol 168: 411–420
Yen D, Cheung J, Scheerens H et al (2006) IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116: 1310–1316
Author information
Authors and Affiliations
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Mudter, J., Yu, J., Amoussina, L. et al. IRF4 selectively controls cytokine gene expression in chronic intestinal inflammation. Arch. Immunol. Ther. Exp. 57, 369–376 (2009). https://doi.org/10.1007/s00005-009-0046-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00005-009-0046-5